Lippiza

Pitavastatin, the active ingredient in Lippiza, is a HMG‑CoA reductase inhibitor presented as an oral tablet for oral use. It lowers elevated cholesterol levels and is used to reduce cardiovascular risk in patients with dyslipidaemia.

GNH USA supplies Lippiza as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pitavastatin acts on lipid metabolism and is indicated for several cholesterol‑related conditions. - Hypercholesterolemia: reduces low‑density lipoprotein (LDL) cholesterol and total cholesterol levels. - Familial hypercholesterolemia: helps achieve target lipid levels in genetically high‑cholesterol patients. - Prevention of cardiovascular events in dyslipidaemia: lowers the risk of heart attack, stroke and related complications in patients with abnormal lipid profiles.

Adverse reactions may occur with pitavastatin therapy.

Common Side Effects: - Headache: mild to moderate intensity. - Muscle pain (myalgia): aching or soreness in skeletal muscles. - Abdominal discomfort: nausea, dyspepsia or flatulence. - Constipation: reduced bowel movements. - Dizziness: transient light‑headedness. - Elevated liver enzymes: mild increases in ALT/AST.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with potential renal injury. - Significant liver injury: marked elevation of hepatic transaminases. - Severe allergic reaction: rash, angioedema or anaphylaxis. - Myopathy: persistent muscle weakness with CK elevation. - Pancreatitis: acute abdominal pain with elevated pancreatic enzymes. - Interstitial lung disease: rare pulmonary inflammation presenting with cough and dyspnea.

Before initiating therapy, clinicians should consider several safety measures. - Liver function monitoring: assess baseline ALT/AST and repeat periodically. - Renal function assessment: evaluate creatinine clearance, especially in elderly patients. - Muscle symptom vigilance: educate patients to report unexplained muscle pain or weakness. - Drug interaction review: avoid concomitant use with strong CYP3A4 inhibitors. - Contraindication in active liver disease: do not prescribe to patients with unexplained persistent hepatic dysfunction. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Pitavastatin may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): can markedly increase pitavastatin exposure. - Gemfibrozil: raises risk of myopathy and rhabdomyolysis. - Cyclosporine: enhances statin plasma concentrations. - Protease inhibitors (e.g., ritonavir): potentiate statin levels. - High‑dose niacin: increases risk of muscle toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: may affect anticoagulation control; monitor INR. - Digoxin: potential for altered serum concentrations. - Antacids containing aluminum or magnesium: may reduce absorption; separate dosing. - Beta‑blockers: monitor for additive effects on heart rate. - Other statins: avoid combination therapy unless specifically indicated and closely supervised.